A previous meta-analysis showed promising results, demonstrating that the combination of CDK4/6i with endocrine therapy improved iDFS in patients with early-stage HR+/HER2− breast cancer compared with those who were treated with hormone therapy alone [14]. This evidence concerns the gene CDK4 and breast cancer.